FDA warns on Ranbaxy Indian-made drugs, blocks import of 30 generic drugs
The warning letters identify the agency’s concerns about deviations from US current Good Manufacturing Practice (cGMP) requirements at Ranbaxy’s manufacturing facilities in Dewas and Paonta Sahib (including the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.